After trial win, Novartis nabs COVID drug from Molecular Partners
There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an […]
There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an […]
Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights […]
Seelos’ SLS-005 (Trehalose) Receives EC’s Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis Published: May 28, 2021 | Tags: Seelos, SLS-005, Trehalose, EC, Orphan Drug […]
Shots: The P-II/II EMPATHY study will evaluate the safety & efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, […]
Shots: The P-II/II EMPATHY study will evaluate the safety & efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, […]
Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, […]
Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, […]
Shots: The P-III ACTIV-3 trial plan to evaluate the safety & efficacy of Ensovibep (MP0420) vs PBO in 300 patients hospitalized with mild to moderate […]
Shots: Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along […]
Copyright © 2024 | WordPress Theme by MH Themes